摘要
急性早幼粒细胞白血病(APL)是目前发病机制了解最清楚的血液系统恶性肿瘤。维甲酸和三氧化二砷直接针对PML—RARα融合蛋白的治疗使得该疾病成为肿瘤靶向治疗的第一个模型,各种新型治疗方案也得到了广泛的关注。现对APL的发病机制及最新的临床治疗进展进行总结和讨论。
Pathogenesis of acute promyelocytic leukemia is one of the best understood disease among human hematological malignancies. Becasue of retinoic acid (RA) and arsenic trioxide which directly target the oncogenic promyelocytic leukemia-retinoic receptor A (PML-RARα) fusion protein, this disease became the first model for oneogene-targeted therapies.And other new therapy methods also gain great concern. The complexity of recent views of acute promyelocytic leukemia pathogenesis, as well as latest progress in clinical treatment were summarized and discussed in this review.
出处
《白血病.淋巴瘤》
CAS
2009年第10期636-638,共3页
Journal of Leukemia & Lymphoma